Gabapentin and pregabalin are γ-aminobutyric acid analogues.1 Gabapentin (Neurontin; Pfizer) was approved by the US Food and Drug Administration (FDA) in 1993 for seizure disorders and postherpetic neuralgia; it became available as a generic in 2004. Two extended-release versions are marketed as brand-name products: Gralise (Assertio Therapeutics) and Horizant (Arbor Pharmaceuticals). Pregabalin (Lyrica; Pfizer) was approved in 2004 for seizure disorders, postherpetic neuralgia, neuropathic pain, and fibromyalgia; a generic formulation is not available. Patient use of gabapentinoids has increased from 1.2% of US adults in 2002 to 3.9% in 2015,2 raising concerns about appropriate use.3 We examined associations between industry payments to physicians associated with gabapentinoids and physicians’ prescribing.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Rhee TG, Ross JS. Association Between Industry Payments to Physicians and Gabapentinoid Prescribing. JAMA Intern Med. Published online July 08, 2019. doi:10.1001/jamainternmed.2019.1082
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: